Spinal Metastasis

Overview

Spinal metastasis refers to secondary involvement of the vertebral column (and sometimes the epidural space, spinal cord, or its surrounding membranes) by malignant cells that have spread from a cancer elsewhere in the body. The spine is the most common site of skeletal metastasis. The vertebral bodies are affected far more often than the posterior elements because their rich red marrow and venous drainage favor tumor seeding.

Spread to the spine is predominantly hematogenous. The valveless Batson vertebral venous plexus provides a direct route for retrograde tumor dissemination, particularly to the thoracic and lumbar segments. As deposits grow, they replace normal bone, weakening the vertebra. If they expand into the epidural space, they can threaten the spinal cord and nerve roots: a complication called metastatic epidural spinal cord compression, the most serious mechanical consequence of spinal metastasis.

Spinal metastases are common and becoming more frequent as cancer survival improves. The vertebral lesions may be osteolytic (bone-dissolving), osteoblastic (bone-hardening), or mixed, depending on the biology of the primary tumor.

What causes it

Any malignancy can reach the spine, but certain tumor types are strongly bone-seeking. In women, breast cancer is the most common source. In men, prostate and lung cancers predominate. Other frequent primary sites include the kidney (renal cell carcinoma), thyroid, and blood cancers such as multiple myeloma. Lung, renal, and thyroid lesions tend to be osteolytic and are more prone to pathologic fracture. Prostate lesions are typically osteoblastic, while breast lesions are frequently mixed or osteolytic.

The principal risk factor is a known or occult malignancy. Risk rises with advanced stage, longer disease duration, and tumor types with a strong tendency to seed bone. Older adults are disproportionately affected because the underlying cancers are more prevalent with age. Occasionally, a spinal metastasis is the first sign that cancer is present before a primary tumor has been identified.

Symptoms and warning signs

The hallmark is progressive axial back or neck pain that is characteristically worse at night or at rest, the opposite of typical mechanical, degenerative back pain that eases with lying down. If a nerve root is involved, pain may radiate into the arm or leg in a specific pattern. If a vertebra collapses from tumor involvement, pain often becomes worse with movement, reflecting instability.

Constitutional warning signs (unexplained weight loss, fatigue, fever, or a personal history of cancer) should prompt urgent evaluation alongside any new or worsening spinal pain.

Neurologic compromise is a medical emergency. Progressive weakness in the legs or arms, new numbness or sensory loss, difficulty walking, or sudden bladder or bowel dysfunction may signal that the spinal cord or cauda equina is being compressed. Functional recovery depends strongly on how quickly treatment is initiated and on the patient's neurologic status at the time treatment begins. Without treatment, the natural history can progress from escalating pain and vertebral instability to irreversible paralysis.

How it's diagnosed

Diagnosis integrates clinical history with imaging. Plain X-rays are insensitive early (roughly half of trabecular bone must be lost before a lytic lesion becomes visible), though they may reveal vertebral collapse, pedicle erosion, or the classic "absent pedicle" sign.

MRI of the entire spine with and without contrast is the investigation of choice. It shows marrow replacement, epidural extension into the spinal canal, and the degree of cord or cauda equina compression in the most detail and without radiation. CT clarifies bony architecture, distinguishes lytic from blastic disease, and guides assessment of mechanical stability and surgical planning. Bone scintigraphy and PET scan help map the full extent of skeletal and systemic disease.

Image-guided biopsy is often essential to establish the tissue diagnosis, particularly when a solitary lesion of unknown primary is found. All imaging findings must always be correlated with the patient's clinical picture and oncologic history, rather than interpreted in isolation.

Treatment options

Management is multidisciplinary (typically involving oncology, radiation oncology, and spine surgery) and is tailored to neurologic status, spinal stability, tumor radiosensitivity, overall prognosis, and the patient's general condition.

Supportive care includes pain management, spinal bracing for painful or unstable segments, and corticosteroids to reduce vasogenic edema around a compressed spinal cord.

Radiation therapy (conventional external beam or stereotactic body radiation) is a cornerstone for pain control and local tumor management, particularly for radiosensitive histologies without overt spinal instability.

Systemic therapies address overall disease burden and may include chemotherapy, hormonal therapy, targeted agents, and bone-modifying drugs such as bisphosphonates or denosumab to reduce skeletal-related events including fracture.

Vertebral augmentation (kyphoplasty or vertebroplasty) is a minimally invasive option for painful compression fractures caused by metastatic disease when the spinal canal is not significantly compromised.

When surgery is considered

Surgery is indicated for symptomatic spinal cord compression amenable to decompression, mechanical instability or pathologic fracture, intractable pain unresponsive to other measures, the need for a tissue diagnosis, or progressive neurologic deficit despite radiation or systemic therapy.

The scope of surgery ranges from minimally invasive vertebral augmentation to circumferential decompression with instrumented stabilization, and is often combined with postoperative radiation to improve local control. For acute or rapidly progressive cord compression, emergent surgical decompression should be considered in patients with a reasonable life expectancy, because delays directly worsen the chance of neurologic recovery.

The decision to operate is always individualized, weighing the expected benefit against the patient's overall health and the goals of care within their broader oncologic context.